Lee, Jun A. Roh, Eun Joo Oh, Chang-Hyun Lee, So Ha Sim, Taebo Kim, Jong Seung Yoo, Kyung Ho 2024-01-20T06:32:21Z 2024-01-20T06:32:21Z 2021-09-05 2015-08 1475-6366 https://pubs.kist.re.kr/handle/201004/125178 Synthesis of a new series of quinolinylaminopyrimidines 1a-k and quinazolinylmethylaminopyrimidines 2a-i containing aminoquinoline and aminoquinazoline as hinge regions is described. Their in vitro antiproliferative activities against A375P human melanoma cell line were tested. Among them, compounds 1h and 1k exhibited the highest antiproliferative activities against A375P cell line with IC50 values in sub-micromolar scale. Compounds 1i, 2b and 2g showed similar potency against A375P to Sorafenib as a reference compound. The representative compound 1h showed high, dose-dependent inhibition of MEK and ERK kinases. English TAYLOR & FRANCIS LTD SCAFFOLD SYNTHESIS KINASE INHIBITION DERIVATIVES DESIGN DIARYLAMIDES DIARYLUREAS SORAFENIB DIAGNOSIS THERAPY Synthesis of quinolinylaminopyrimidines and quinazolinylmethylaminopyrimidines with antiproliferative activity against melanoma cell line Article 10.3109/14756366.2014.958082 1 JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, v.30, no.4, pp.607 - 614 JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY 30 4 607 614 scie scopus 000359816600014 2-s2.0-84937211369 Biochemistry & Molecular Biology Chemistry, Medicinal Biochemistry & Molecular Biology Pharmacology & Pharmacy Article SCAFFOLD SYNTHESIS KINASE INHIBITION DERIVATIVES DESIGN DIARYLAMIDES DIARYLUREAS SORAFENIB DIAGNOSIS THERAPY Antiproliferative MEK/ERK kinase inhibition melanoma cell line quinazoline quinoline